Treatment of herpes retinitis in an animal model with a sustained delivery antiviral drug, liposomal 1-O-octadecyl-SN-glycerol-3-phosphonoformate.

Abstract

PURPOSE:

To evaluate the clinical treatment efficacy of a long-lasting intravitreous injectable anti-cytomegalovirus (CMV) liposomal drug, 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA).

METHODS:

Sixty-four pigmented rabbits were used for evaluation of the potency and duration of action of ODG-PFA after intravitreal injection using a herpes simplex virus (HSV)-1 retinitis model. For the potency evaluation, liposomal ODG-PFA was injected into rabbit vitreous at the same time that HSV-1 virus was inoculated onto the retina (simultaneous treatment). For the duration evaluation, ODG-PFA was injected days or weeks before inoculation (pretreatment). Retinitis was clinically graded by indirect ophthalmoscopy, and the retinitis scores were compared across the treatment and control groups.

RESULTS:

Simultaneous treatment study revealed that ODG-PFA was much more potent than its parent compound, foscarnet (P = 0.0027). Pretreatment study indicated that ODG-PFA possesses a much longer antiviral effect (at least 2 weeks) than foscarnet after a single intravitreal injection.

CONCLUSION:

Liposomal ODG-PFA is a potent long-lasting intravitreal injectable antiviral compound that may be an ideal alternative for treatment of CMV retinitis in patients with acquired immunodeficiency syndrome.

• Authors: L Cheng, K Y Hostetler, S Chaidhawangul, M F Gardner, U Ozerdem, G Bergeron-Lynn, B Mach-Hofacre, A J Mueller, G M Severson, W R Freeman
• Journal: Retina (Philadelphia, Pa.) (Retina) Vol. 19 Issue 4 Pg. 325-31 ( 1999) ISSN: 0275-004X [Print] United States
• PMID: 10458299 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• 1-O-octadecyl-sn-glycerol-3-phosphonoformate
• Antiviral Agents
• Delayed-Action Preparations
• Drug Carriers
• Liposomes
• Phospholipid Ethers
• Foscarnet

Topics

• Animals
• Antiviral Agents (administration & dosage)
• Delayed-Action Preparations
• Disease Models, Animal
• Drug Carriers
• Eye Infections, Viral (drug therapy, pathology, virology)
• Follow-Up Studies
• Foscarnet (administration & dosage, analogs & derivatives)
• Herpes Simplex (drug therapy, pathology, virology)
• Herpesvirus 1, Human (isolation & purification, pathogenicity)
• Liposomes
• Phospholipid Ethers (administration & dosage)
• Rabbits
• Retina (pathology, virology)
• Retinitis (drug therapy, pathology, virology)
• Treatment Outcome